Contact:
4008465777
-
About Us
News & Events
-
10-20
Tonghua Dongbao receives registration approval for Insulin Aspart and Sitagliptin Metformin Tablets (II)
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") received the Registration Approval for Insulin Aspart and Sitagliptin Metformin Tablets (II) from the National M...
-
10-12
Tonghua Dongbao: BC Lispro is approved for parallel Phase III and Phase I clinical trials
On 28 March 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. (the Company or Tonghua Dongbao) submitted to the Center for Drug Evaluation of the National Medical Products Administration (the CDE) an app...
-
10-20
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for URAT1 inhibitor (THDBH130 Tablets)
On 11 October 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the Company or Tonghua Dongbao),recei...
-
10-20
Tonghua Dongbao selected as one of top 100 most valuable Mainboard-listed companies
On September 28, Securities Times and Caitong Securities published the Ranking of Listed Companies in China by Value for 2021. Tonghua Dongbao Pharmaceutical Co., Ltd. (Tonghua Dongbao or the Company)...
-
09-06
Tonghua Dongbao taps into new market with its first approved oral hypoglycemic drug
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or “the Company”) received the Pharmaceutical Product Registration Certificate for sitagliptin phosphate tablets issued by the National...
-
08-24
Tonghua Dongbao reports YoY increase of 24.47% in net profit for H1 2021 as profitability continues to improve
On the evening of August 24, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2021 half-year report. In H1 2021...